Estrella Immunopharma (NASDAQ:ESLA) · earnings miss
Quarter
Q3
EPS estimate to actual
-$0.08→ to -$0.17
Revenue estimate to actual
$0.0→ to $0.0
At a glance
Key takeaways
01Estrella Immunopharma reported Q3 earnings per share of -$0.17, missing the consensus estimate of -$0.08 by $0.09 per share on November 16, 2026.
02The earnings miss represents a 112% negative surprise relative to consensus estimates, a notably large deviation that often triggers analyst revisions.
03The stock trades at $0.51 with a market capitalization of $70.2M following the disappointing results.
04Recent earnings history shows the company beat expectations in the previous three quarters, making this Q3 miss a reversal of that trend.
05Revenue met analyst expectations, suggesting the earnings miss was driven by operating costs or other expenses rather than sales weakness.
Earnings Results
Estrella Immunopharma (NASDAQ:ESLA) reported quarterly earnings results on November 16, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.17, missing the consensus estimate of $-0.08 by $0.09 per share. Revenue came in at , meeting the estimate of .
Company Overview
Estrella Immunopharma's stock moved following the earnings release. The stock currently trades at $0.51 with a market capitalization of $70.2M.
Missing analyst estimates puts pressure on a stock as investors reassess their growth assumptions. The market's reaction to an earnings miss depends heavily on the magnitude of the shortfall, the company's forward guidance, and whether the miss was driven by temporary or structural factors.
The 112% miss relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Estrella Immunopharma should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.